PROLOR Biotech,
Inc. (NYSE: PBTH), today announced that the company will present new
results from preclinical studies of its long-acting clotting factor VIIa
(Factor VIIa-CTP), a next-generation investigational therapy in advanced
preclinical development for the potential treatment of hemophilia. The data
provide further evidence that Factor VIIa-CTP has the potential to be
administered by subcutaneous (SC) injection as well as intravenously (IV),
which would facilitate its prophylactic use by patients on an ongoing basis.
The study results will be discussed in an oral presentation at the XXIV
Congress of the International Society of Hemostasis and Thrombosis (ISTH).

Currently available commercial factor VIIa must be administered through IV
infusion, which can be onerous for patients. This limits its use for
prophylactic treatment and can require frequent administrations if patients
are treated only "on demand" when a bleeding episode occurs.

The new preclinical results being presented at the ISTH Congress further
confirm the efficacy of PROLOR's long-acting Factor VIIa-CTP and show that it
has the potential to be administered using a simple SC injection. The
combination of a long-acting product coupled with the ability to be
administered by SC injection could change the way that factor VIIa is used,
potentially allowing individuals with hemophilia to self-administer the drug
at home on a prophylactic basis, improving their quality of life and
potentially reducing the need for on-demand treatment of bleeding episodes.